Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9943218 | The American Journal of Pathology | 2005 | 7 Pages |
Abstract
The enzyme 12/15 lipoxygenase (12/15LO) has been implicated in the oxidative modification of lipoproteins and phospholipids in vivo. In addition, mice deficient in apolipoprotein E (ApoEâ/â) are characterized by spontaneous hypercholesterolemia and a systemic increase in oxidative stress. Whereas the absence of 12/15LO reduces lipid peroxidation in the plasma and urine of ApoEâ/â mice, the relative contribution of this enzyme to oxidative stress in the central nervous system remains unknown. Here, we provide the first in vivo evidence that 12/15LO modulates brain oxidative stress reactions using ApoEâ/â mice crossbred with 12/15LO-deficient (12/15LOâ/â) mice (12/15LOâ/â/ApoEâ/â). In chow-fed 12-month-old 12/15LOâ/â/ApoEâ/â mice, the amount of brain isoprostane iPF2α-VI, a marker of lipid peroxidation, and carbonyls, markers of protein oxidation, were significantly reduced when com-pared with 12/15LO-expressing controls (12/15LO+/+/ApoEâ/â). These results were observed despite the fact that cholesterol, triglyceride, and lipoprotein levels were similar to those of ApoEâ/â mice. These data indicate a functional role for 12/15LO in the modulation of oxidative reactions in the central nervous system, supporting the hypothesis that inhibition of this enzymatic pathway may be a novel therapeutic target in clinical settings involving increased brain oxidative stress.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Cinzia M. Chinnici, Yuemang Yao, Tao Ding, Colin D. Funk, Domenico Praticò,